^
Association details:
| Biomarker: | PIK3CA mutation + HRAS mutation |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated HNSCC.
Published date:
05/28/2020
Excerpt:
Regressions with the FTI-PI3K-a inhibitor doublet were observed both in tumors that were WT or harbored hotspot mutations or amplification of the PIK3CA gene and in HRAS mutants that carried or lacked PIK3CA mutations.
DOI:
10.1200/JCO.2020.38.15_suppl.e15658
